Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease

Related Clinical Trial
Propranolol and Von Hippel-Lindau Disease Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease? Phase II Study of Vandetanib in Individuals With Kidney Cancer A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Drivers of Hypoxia-induced Angiogenesis in Tumor Development Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors MyVHL: Patient Natural History Study Metabolic Mapping to Measure Retinal Metabolism Use of Tracking Devices to Locate Abnormalities During Invasive Procedures National Eye Institute Biorepository for Retinal Diseases Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Pazopanib in Von Hippel-Lindau (VHL) Syndrome 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Von Hippel-Lindau Disease Genetic Epidemiology Study Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 TKI 258 in Von Hippel-Lindau Syndrome (VHL) Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome

Brief Title

Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease

Official Title

A Single-arm, Phase II Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease

Brief Summary

      VHL patients may benefit from sunitinib. This study will investigate the following objectives


        -  To determine the objective response rate according to RECIST criteria, in VHL patients
           with advanced tumors or tumors untreatable by other means, and treated with sunitinib.


        -  To evaluate the safety and tolerability of sunitinib in VHL patients according to the
           NCI-CTC criteria Version 3.0.

        -  To determine the following time-to-event endpoints: overall survival, time to disease
           progression, progression free survival, time to response and duration of response.

        -  To evaluate quality of life in VHL patients receiving sunitinib.

Detailed Description

      Treatment with sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of
      treatment followed by 2 weeks of rest).

      Treatment until disease progression or unacceptable toxicity.

      Dose reduction depending on type and severity of toxicity. At the end of treatment period
      (after 8 courses), responding and well tolerating patients will be allowed to receive
      sunitinib upon investigator's opinion.

      Follow-up for up to 24 months from inclusion.

Study Phase

Phase 2

Study Type


Primary Outcome

Objective response rate (RECIST criteria)

Secondary Outcome

 Safety and tolerability (NCI-CTC criteria Version 3.0).


Von Hippel-Lindau Disease




* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 2010

Completion Date

February 2011

Primary Completion Date

February 2011

Eligibility Criteria


          1. Patients must have genetically or clinically confirmed VHL disease and have symptoms
             from VHL that are no longer controllable by conventional approaches.

          2. Patients must have at least one of the following lesions :

               -  Eye : retinal hemangioblastoma that can no longer be treated by laser therapy or
                  cryotherapy and resulting in progressive loss of vision;

               -  CNS : cerebellar, bulbar, spinal, or cerebellopontine angle haemangioblastoma or
                  endolymphatic sac tumor causing neurological symptoms that are not amenable to
                  further surgery, or have recurred after a first surgery;

               -  Kidney: multiple or bilateral tumors not accessible to conservative surgery, or
                  tumors having recurred after surgery and/or radiofrequency ablation or
                  advanced/metastatic RCC;

               -  Pancreas: inextirpable or advanced neuroendocrine tumors.

          3. Patients previously treated for VHL with surgery, chemotherapy or radiotherapy are
             considered eligible for this study under the condition that these treatments were
             completed more than 4 weeks prior starting the study treatment. Previously radiated
             lesions will be considered as target lesions only if they demonstrate unequivocal
             evidence of growth upon imagery.

          4. Male or female, at least 18 year-old.

          5. Performance status ECOG 0-2

          6. Life expectancy = 3 months

          7. Biological/clinical values within the following limits:

               -  Total serum bilirubin = 1.5 x ULN (patients with Gilbert's disease are not

               -  Serum transaminases and alkaline phosphatases = 2.5 x ULN, or in case of
                  underlying malignancy (hepatic metastasis) = 5x ULN

               -  Serum creatinine = 1.5 x ULN, creatinine clearance = 80 ml/min

               -  Absolute neutrophil count = 1500/mm3

               -  Platelets = 100,000/mm3

               -  Hemoglobin = 9.0 g/dL

               -  QTc interval = 450 msec

               -  Left ventricular ejection fraction (LVEF) = lower limit of institutional normal
                  as assessed by multigated acquisition (MUGA) scan or echocardiogram

          8. Eligibility of patients receiving any medications or substances which may alter the
             activity or pharmacokinetics of sunitinib (CYP3A4 inhibitors or inducers among which
             ketoconazole, theophylline, phenobarbital, coumadin/warfarin) will be decided after
             review by the principal investigator of possibility to interrupt or switch to other
             medications. Otherwise, patient is not eligible. Anticoagulants drugs (among which
             coumadin/warfarin) may be, either switched to low-molecular-weight heparin, or be
             subject to individual dose adaptation in order to maintain INR in the target range
             with regard to patient's history, all along his participation in the study.

          9. Signed and dated informed consent document stating that the patient, or legally
             representative, has been informed of all the aspects of the trial prior to enrollment

         10. Willingness and ability to comply with all protocol assessments, schedule of visits,
             and procedures that are or could be requested as part of this study.

         11. Affiliated to French social security system


          1. Chemotherapy, radiotherapy, radiofrequency or surgery within 4 weeks prior to entering
             the study or not complete recovering from adverse events due to drugs administered
             more than 4 weeks earlier.

          2. Patients receiving any other investigational agent or having participated in a
             clinical trial in the last 30 days.

          3. History of allergic reaction attributed to compounds of similar chemical or biological
             composition to sunitinib.

          4. Previous treatment with sunitinib

          5. NCI-CTCAE grade = 3 hemorrhage within 4 weeks prior to study entry.

          6. History of known or suspected brain metastases, spinal cord compression, carcinomatous
             meningitis, evidence of leptomeningeal disease (excepted leptomeningeal
             hemangioblastoma, according to the neurologist) on screening CT scan or MRI.

          7. Any of the following within the 6 months prior to study drug administration:
             symptomatic congestive heart failure, myocardial infarction or coronary artery bypass,
             pulmonary embolism, ongoing severe or unstable angina pectoris, NCI-CTCAE grade = 2
             cardiac dysrhythmia, cerebrovascular accident or transient ischemic attack.

          8. Hypertension >140/90 mmHg that cannot be controlled despite optimal antihypertensive

          9. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range despite medication.

         10. Other severe acute or chronic medical condition including (but not limited to),
             ongoing infection, unstable or uncompensated respiratory, cardiac, hepatic or renal
             disease, psychiatric condition, laboratory abnormality that would impart, in the
             judgment of the investigator, excess risk associated with study participation or study
             drug administration, or which would make the patient inappropriate for entry into the

         11. Any medical condition (gastric or small intestine pathology, malabsorption syndrome)
             that might interfere with oral medication absorption.

         12. Known HIV-positive patients treated with antiretroviral therapy (potential
             pharmacokinetic interactions with sunitinib).

         13. Pregnancy or breastfeeding. Patients must agree to use effective contraception during
             the study, including oral contraceptives, intrauterine devices, or being unable to

         14. Any other malignancy within the last 3 years excepted basal cell carcinoma, in situ
             cervical carcinoma, squamous cell skin cancer, pT1/a bladder cancer with no evidence
             of recurrence during the last 12 months.




18 Years - 90 Years

Accepts Healthy Volunteers



Stephane RICHARD, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Study Sponsor

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Study Sponsor

Stephane RICHARD, MD, PhD, Principal Investigator, Hôpital Kremlin-Bicêtre (France)

Verification Date

September 2012